Given that ectopic lipid accumulation and lipotoxicity-induced inflammation are key drivers of NAFLD and NASH progression [38], GP was shown to alleviate these pathological features by regulating AMPK and inflammatory markers such as F4/80, TNF-α, and IL-6 (Figure 6). The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.